Predicting, Diagnosing, and Treating Acute and Early HIV Infection in a Public Sector Facility in Eswatini

J Acquir Immune Defic Syndr. 2021 Dec 15;88(5):506-517. doi: 10.1097/QAI.0000000000002794.

Abstract

Background: The lack of acute and early HIV infection (AEHI) diagnosis and care contributes to high HIV incidence in resource-limited settings. We aimed to assess the yield of AEHI, predict and diagnose AEHI, and describe AEHI care outcomes in a public sector setting in Eswatini.

Setting: This study was conducted in Nhlangano outpatient department from March 2019 to March 2020.

Methods: Adults at risk of AEHI underwent diagnostic testing for AEHI with the quantitative Xpert HIV-1 viral load (VL) assay. AEHI was defined as the detection of HIV-1 VL on Xpert and either an HIV-seronegative or HIV-serodiscordant third-generation antibody-based rapid diagnostic test (RDT) result. First, the cross-sectional analysis obtained the yield of AEHI and established a predictor risk score for the prediction of AEHI using Lasso logistic regression. Second, diagnostic accuracy statistics described the ability of the fourth-generation antibody/p24 antigen-based Alere HIV-Combo RDT to diagnose AEHI (vs Xpert VL testing). Third, we described acute HIV infection care outcomes of AEHI-positive patients using survival analysis.

Results: Of 795 HIV-seronegative/HIV-serodiscordant outpatients recruited, 30 (3.8%, 95% confidence interval: 2.6% to 5.3%) had AEHI. The predictor risk score contained several factors (HIV-serodiscordant RDT, women, feeling at risk of HIV, swollen glands, and fatigue) and had sensitivity and specificity of 83.3% and 65.8%, respectively, to predict AEHI. The HIV-Combo RDT had sensitivity and specificity of 86.2% and 99.9%, respectively, to diagnose AEHI. Of 30 AEHI-positive patients, the 1-month cumulative treatment initiation was 74% (95% confidence interval: 57% to 88%), and the 3-month viral suppression (<1000 copies/mL) was 87% (67% to 98%).

Conclusion: AEHI diagnosis and care seem possible in resource-limited settings.

MeSH terms

  • Acute Disease
  • Adult
  • Anti-Retroviral Agents / therapeutic use*
  • Cross-Sectional Studies
  • Early Diagnosis
  • Eswatini / epidemiology
  • Female
  • HIV Antibodies / blood*
  • HIV Core Protein p24
  • HIV Infections* / diagnosis
  • HIV Infections* / drug therapy
  • HIV-1 / immunology*
  • Humans
  • Predictive Value of Tests
  • Public Sector
  • Sensitivity and Specificity
  • Time Factors

Substances

  • Anti-Retroviral Agents
  • HIV Antibodies
  • HIV Core Protein p24